PDCD1 and cancer: Accordingly, we obtained peripheral T cells from NSCLC patients initiating ICI following front-line chemotherapy and assessed proliferation ex vivo using a T cell stimulator cell line, described elsewhere [15], that models recognition of cancer cells by T cells in the presence of inhibitory signalling through both PD1 and LAG3 axes.